Treatment of hepatitis B virus-associated nephropathy

Nephron - Clinical Practice

Volumn 119, Issue 1, 2011, Pages

  Elewa, Usama ^a   Sandri, Ana Maria ^b   Kim, W Ray ^c   Fervenza, Fernando C ^d  

^a Cairo University   (Egypt)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c MAYO CLINIC   (United States)

^d Mayo Clinic College of Medicine   (United States)

Author keywords

Antiviral therapy; Hepatitis B virus; Immunosuppressive therapy; Nephropathy

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RITUXIMAB; TELBIVUDINE; TENOFOVIR;

ALOPECIA; ANOREXIA; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BLOOD TOXICITY; CORTICOSTEROID THERAPY; DEPRESSION; DERMATITIS; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FANCONI RENOTUBULAR SYNDROME; FLU LIKE SYNDROME; GEOGRAPHIC DISTRIBUTION; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS ASSOCIATED NEPHROPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; LIVER TOXICITY; MEMBRANOUS GLOMERULONEPHRITIS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REMISSION; REVIEW; SEX DIFFERENCE; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTIVIRAL AGENTS; GLOMERULONEPHRITIS, MEMBRANOUS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; PROTEINURIA; TREATMENT OUTCOME;

EID: 79958768910     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000324652     Document Type: Review

References (75)

1. Liver EAFTSOT: EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
2. Sorrell MF, Belongia EA, Costa J, Gareen IF, et al: National Institutes of Health Consensus Development Conference Statement: Management of hepatitis B. Ann Intern Med 2009; 150: 104-110.
3. Abbas NA, Pitt MA, Green AT, Solomon LR: Successful treatment of hepatitis B virus (HBV)-associated membranoproliferative glomerulonephritis (MPGN) with alpha interferon. Nephrol Dial Transplant 1999; 14: 1272-1275. (Pubitemid 29209324)
4. Conjeevaram HS, Hoofnagle JH, Austin HA, Park Y, et al: Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 1995; 109: 540-546.
5. Lisker-Melman M, Webb D, Di Bisceglie AM, Kassianides C, et al: Glomerulonephritis caused by chronic hepatitis B virus infection: Treatment with recombinant human alpha-interferon. Ann Intern Med 1989; 111: 479-483. (Pubitemid 19231305)
6. Brzosko WJ, Krawczynski K, Nazarewicz T, Morzycka M, et al: Glomerulonephritis associated with hepatitis-B surface antigen immune complexes in children. Lancet 1974; 2: 477-482.
7. Lai KN, Lai FM, Tam JS, Chow CB, et al: High prevalence of hepatitis B surface antigenaemia in nephrotic syndrome in Hong Kong. Ann Trop Paediatr 1989; 9: 45-48. (Pubitemid 19122491)
8. Lai KN, Lai FM, Lo S, Leung A: Is there a pathogenetic role of hepatitis B virus in lupus nephritis? Arch Pathol Lab Med 1987; 111: 185-188. (Pubitemid 17015620)
9. Looi LM, Prathap K: Hepatitis B virus surface antigen in glomerular immune complex deposits of patients with systemic lupus erythematosus. Histopathology 1982; 6: 141-147. (Pubitemid 12150072)
10. Khaira A, Upadhyay BK, Sharma A, Das P, et al: Hepatitis B virus associated focal and segmental glomerular sclerosis: Report of two cases and review of literature. Clin Exp Nephrol 2009; 13: 373-377.
11. Lai KN, Lai FM, Lo S, Ho CP, et al: IgA nephropathy associated with hepatitis B virus antigenemia. Nephron 1987; 47: 141-143. (Pubitemid 17147991)
12. Bhimma R, Coovadia HM, Adhikari M: Hepatitis B virus-associated nephropathy in black South African children. Pediatr Nephrol (Berlin) 1998; 12: 479-484. (Pubitemid 28396036)
13. Bhimma R, Coovadia HM, Kramvis A, Adhikari M, et al: HBV and proteinuria in relatives and contacts of children with hepatitis B virus-associated membranous nephropathy. Kidney Int 1999; 55: 2440-2449. (Pubitemid 29256499)
14. Gilbert RD, Wiggelinkhuizen J: The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol (Berlin) 1994; 8: 11-14. (Pubitemid 24042358)
15. Seggie J, Nathoo K, Davies PG: Association of hepatitis B (HBs) antigenaemia and membranous glomerulonephritis in Zimbabwean children. Nephron 1984; 38: 115-119. (Pubitemid 14058576)
16. Coovadia HM, Adhikari M, Morel-Maroger L: Clinico-pathological features of the nephrotic syndrome in South African children. Q J Med 1979; 48: 77-91. (Pubitemid 9222275)
17. Takekoshi Y, Tanaka M, Shida N, Satake Y, et al: Strong association between membranous nephropathy and hepatitis-B surface antigenaemia in Japanese children. Lancet 1978; 2: 1065-1068. (Pubitemid 9052859)
18. Lai KN, Lai FM, Chan KW, Chow CB, et al: The clinico-pathologic features of hepatitis B virus-associated glomerulonephritis. Q J Med 1987; 63: 323-333.
19. Slusarczyk J, Michalak T, Nazarewicz-de Mezer T, Krawczynski K, et al: Membranous glomerulopathy associated with hepatitis B core antigen immune complexes in children. Am J Pathol 1980; 98: 29-43. (Pubitemid 10176933)
20. Lai KN, Lai FM, Lo ST, Lam CW: IgA nephropathy and membranous nephropathy associated with hepatitis B surface antigenemia. Hum Pathol 1987; 18: 411-414. (Pubitemid 17071045)
21. Lai KN, Lai FM, Tam JS: IgA nephropathy associated with chronic hepatitis B virus infection in adults: The pathogenetic role of HBsAG. J Pathol 1989; 157: 321-327. (Pubitemid 19111235)
22. Shen LP, Zhang Y, Wang F, Zhang S, et al: Epidemiological changes in hepatitis B prevalence in an entire population after 20 years of the universal HBV vaccination programme. Epidemiol Infect, Epub ahead of print.
23. Zhou FD, Zhao MH, Zou WZ, Liu G, et al: The changing spectrum of primary glomerular diseases within 15 years: A survey of 3,331 patients in a single Chinese centre. Nephrol Dial Transplant 2009; 24: 870-876.
24. Bhimma R, Coovadia HM: Hepatitis B virusassociated nephropathy. Am J Nephrol 2004; 24: 198-211.
25. Lin CY: Hepatitis B virus-associated membraneous nephropathy: Clinical features, immunological profiles and outcome. Nephron 1990; 55: 37-44.
26. Hepatitis B surface antigenemia in North American children with membranous glomerulonephropathy. Southwest Pediatric Nephrology Study Group. J Pediatr 1985; 106: 571-578.
27. Guillevin L, Mahr A, Callard P, Godmer P, et al: Hepatitis B virus-associated polyarteritis nodosa: Clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine 2005; 84: 313-322. (Pubitemid 41368484)
28. Jennette JC, Falk RJ, Andrassy K, Bacon PA, et al: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192. (Pubitemid 24065492)
29. Hsu HC, Lin GH, Chang MH, Chen CH: Association of hepatitis B surface (HBs) antigenemia and membranous nephropathy in children in Taiwan. Clin Nephrol 1983; 20: 121-129. (Pubitemid 13050295)
30. Ito H, Hattori S, Matusda I, Amamiya S, et al: Hepatitis B e antigen-mediated membranous glomerulonephritis. Correlation of ultrastructural changes with HBeAg in the serum and glomeruli. Lab Invest 1981; 44: 214-220. (Pubitemid 11143375)
31. Kleinknecht C, Levy M, Peix A, Broyer M, et al: Membranous glomerulonephritis and hepatitis B surface antigen in children. J Pediatr 1979; 95: 946-952. (Pubitemid 10249780)
32. Knecht GL, Chisari FV: Reversibility of hepatitis B virus-induced glomerulonephritis and chronic active hepatitis after spontaneous clearance of serum hepatitis B surface antigen. Gastroenterology 1978; 75: 1152-1156. (Pubitemid 9039575)
33. Takekoshi Y, Tochimaru H, Nagata Y, Itami N: Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy. Kidney Int Suppl 1991; 35:S34-S39.
34. Lai KN, Li PK, Lui SF, Au TC, et al: Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324: 1457-1463.
35. Lai KN, Lai FM: Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults. Kidney Int Suppl 1991; 35:S40-S45.
36. Appel G: Viral infections and the kidney: HIV, hepatitis B, and hepatitis C. Cleve Clin J Med 2007; 74: 353-360.
37. Kohler PF, Cronin RE, Hammond WS, Olin D, et al: Chronic membranous glomerulonephritis caused by hepatitis B antigen-antibody immune complexes. Ann Intern Med 1974; 81: 448-451.
38. Lau GK, Piratvisuth T, Luo KX, Marcellin P, et al: Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695. (Pubitemid 41007823)
39. Marcellin P, Lau GK, Bonino F, Farci P, et al: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217. (Pubitemid 39296307)
40. Lin CY: Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995; 47: 225-230.
41. Bhimma R, Coovadia HM, Kramvis A, Adhikari M, et al: Treatment of hepatitis B virus- associated nephropathy in black children. Pediatr Nephrol (Berlin) 2002; 17: 393-399. (Pubitemid 36067985)
42. Olsen SK, Brown RS Jr: Hepatitis B treatment: Lessons for the nephrologist. Kidney Int 2006; 70: 1897-1904. (Pubitemid 44863376)
43. Tang S, Lai FM, Lui YH, Tang CS, et al: Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005; 68: 1750-1758. (Pubitemid 43169919)
44. Rostaing L, Henry S, Cisterne JM, Duffaut M, et al: Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64: 1624-1627. (Pubitemid 28047399)
45. Chuang TW, Hung CH, Huang SC, Lee CM: Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy. J Formos Med Assoc 2007; 106: 869-873.
46. Liaw YF, Leung NW, Chang TT, Guan R, et al: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180. (Pubitemid 30452590)
47. Benhamou Y, Thibault V, Vig P, Calvez V, et al: Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44: 62-67. (Pubitemid 41772517)
48. Herreros de Tejada Echanojauregui A, Moreno Planas JM, Rubio Gonzalez E, Portero Azorin F, et al: Adefovir dipivoxil therapy in liver transplant recipients with lamivudineresistant hepatitis B virus. Transplant Proc 2005; 37: 1507-1508. (Pubitemid 40712101)
49. Marcellin P, Chang TT, Lim SG, Tong MJ, et al: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816. (Pubitemid 36245757)
50. Perrillo R, Hann HW, Mutimer D, Willems B, et al: Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90. (Pubitemid 38040726)
51. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, et al: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-2681. (Pubitemid 41007822)
52. Izzedine H, Hulot JS, Launay-Vacher V, Marcellini P, et al: Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney Int 2004; 66: 1153-1158. (Pubitemid 39121022)
53. Fontaine H, Vallet-Pichard A, Chaix ML, Currie G, et al: Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005; 80: 1086-1092. (Pubitemid 41611932)
54. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, et al: Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 1831-1838. (Pubitemid 35408307)
55. Chang TT, Gish RG, de Man R, Gadano A, et al: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010. (Pubitemid 43357804)
56. Lai CL, Shouval D, Lok AS, Chang TT, et al: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020. (Pubitemid 43357805)
57. Marcellin P, Heathcote EJ, Buti M, Gane E, et al: Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455.
58. Verhelst D, Monge M, Meynard JL, Fouqueray B, et al: Fanconi syndrome and renal failure induced by tenofovir: A first case report. Am J Kidney Dis 2002; 40: 1331-1333. (Pubitemid 35403147)
59. Lai KN, Tam JS, Lin HJ, Lai FM: The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 1990; 54: 12-17. (Pubitemid 19284256)
60. Cadrobbi P, Bortolotti F, Zacchello G, Rinaldi R, et al: Hepatitis B virus replication in acute glomerulonephritis with chronic active hepatitis. Arch Dis Childhood 1985; 60: 583-585. (Pubitemid 15005917)
61. Lai FM, Tam JS, Li PK, Lai KN: Replication of hepatitis B virus with corticosteroid therapy in hepatitis B virus related membranous nephropathy. Virchows Archiv 1989; 414: 279-284. (Pubitemid 19069748)
62. Taskapan H, Oymak O, Dogukan A, Ozbakir O, et al: Transformation of hepatitis B virus-related membranous glomerulonephritis to crescentic form. Clin Nephrol 2000; 54: 161-163. (Pubitemid 30625637)
63. Guillevin L, Pagnoux C: Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial 2003; 7: 155-160. (Pubitemid 36753910)
64. Guillevin L, Lhote F, Jarrousse B, Bironne P, et al: Polyarteritis nodosa related to hepatitis B virus. A retrospective study of 66 patients. Ann Med Intern 1992; 143(suppl 1):63-74. (Pubitemid 23043746)
65. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, et al: Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol 2010; 5: 2188-2198.
66. Stone JH, Merkel PA, Spiera R, Seo P, et al: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232.
67. Zhang B, Wang J, Xu W, Wang L, et al: Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: Necessity of antiviral prophylaxis. Onkologie 2010; 33: 537-539.
68. Evens AM, Jovanovic BD, Su YC, Raisch DW, et al: Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports. Ann Oncol, Epub ahead of print.
69. Koo YX, Tan DS, Tan IB, Tao M, et al: Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma. Ann Intern Med 2009; 150: 655-656.
70. Ozgonenel B, Moonka D, Savasan S: Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma. Am J Hematol 2006; 81: 302.
71. Matsue K, Kimura S, Takanashi Y, Iwama K, et al: Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010; 116: 4769-4776.
72. Xunrong L, Yan AW, Liang R, Lau GK: Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management. Rev Med Virol 2001; 11: 287-299. (Pubitemid 33009970)
73. Hamada T, Kumashiro R, Koga Y, Hino T, et al: Fatal acute hepatitis B virus infection while receiving immunosuppressants after renal transplantation. Intern Med 1993; 32: 547-551. (Pubitemid 23360733)
74. Lai MK, Huang CC, Chu SH, Chuang CK, et al: Renal transplantation in hepatitis B carriers: Comparison of azathioprine- and cyclosporine- treated recipients. Clin Transplants 1989; 281-286.
75. Liaw YF, Sung JJ, Chow WC, Farrell G, et al: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.